Plus Therapeutics Expands Collaboration with Piramal Pharma Solutions to Meet Increase in Investigational Drug Demand for Ongoing and Planned Clinical Trials

Plus Therapeutics, Inc. announced an expansion of its collaboration with Piramal Pharma Solutions to produce additional cGMP liposome intermediate drug product to meet the increase in demand for its lead investigational targeted radiotherapeutic, rhenium obisbemeda, for ongoing and planned clinical trials.